arrow_back Back Filing freshness 10-Q Q2 FY2026 SEC EDGAR

CEL SCI CORP

CVM
$1.72 ▲ +0.11 (+6.85%) at close
Healthcare ·Biological Products, (No Diagnostic Substances) ·USBiological Products, (No Diagnostic Substances)
67 Visible periods
24 Metrics
Peer-ranked Benchmarks
Price Chart
18
Health
Poor
Bearish
auto_awesome

Analytical Summary

CEL SCI CORP faces fundamental challenges with weakness in Return on Common Equity (%). The fundamentals warrant careful consideration of downside risks.

Market Cap
Dividend Yield
Revenue Growth None
Op. Margin
ROIC -61.2%
FCF / Share None
Trailing P/E
Price / Book 2.1x
FCF Yield
Debt / Equity
info Valuation on last close. End-of-day price, Aug 7, 2026.

67-Year Financial Trajectory

Quarterly
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$77.40K
↑ +150.5%
Net Income Profit after all expenses
$-5.47M
↑ +22.7%
FCF / Share Free cash flow per share
$-0.11
↑ +2.9%
trending_up

Bullish Indicators

  • No bullish signals detected.
warning

Bearish Risks

  • Return on Common Equity (%)Return on Common Equity (%) is in the bottom quartile

Health Breakdown

Returns
4
Financial Health
19
Cash Quality
47

bar_chart Data from SEC EDGAR XBRL filings

Synced 1 week ago 18 years · 67 quarters